The goal of this study is to apply the IL7/CCL19‐producing technology to make anti-EGFRvIII or HER2 CAR-T more offensive to glioblastoma and pancreatic cancer, so as to improve the therapeutic efficacy. This evidence concerns the gene CCL19 and familial pancreatic carcinoma.